Research & Development
CIVCO Radiotherapy passes US FDA 510k clearance and CE mark for Solstice SRS Immobilization System
16 October 2018 -

Radiotherapy company CIVCO Radiotherapy revealed on Monday the receipt of US FDA 510k clearance and EU CE mark for the Solstice SRS Immobilization System with variable pitch capability and positioning flexibility in aid of patients and doctors in radiotherapy clinics.

The company added that the Solstice SRS Immobilization System will be launched in the market following its display at the American Society for Radiation Oncology (ASTRO) Meeting from 21-24 October 2018 in San Antonio, Texas.

According to the company, the Solstice SRS Immobilization System creates a highly customisable and comfortable head and neck immobilisation system for precise treatment to improve patient outcomes. The system is comprised of a carbon fibre head support, customisable cushion and dedicated thermoplastic mask designed for secure and simple attachment.

In addition, the company's patient-centric solutions include advanced patient immobilisation and positioning hardware and consumables, fiducial markers, couchtops and overlays, software, patient care products and advanced 6DOF robotic patient positioning.